TRAF6 and breast carcinoma: Remarkably, in the context of breast cancer and osteoclast-mediated bone degeneration, a small molecular inhibitor of TRAF6, 6877002, has shown efficacy in reducing metastasis, osteolysis, and osteoclast formation in osteotropic breast cancer models of both human and murine origin 130.